Henan Lingrui Pharmaceutical Co., Ltd. (SHA:600285)
China · Delayed Price · Currency is CNY 19.70
+0.03 (0.15%)
Aug 14, 2026, 3:00 PM CST
SHA:600285 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,897 | 3,848 | 3,498 | 3,307 | 2,998 | 2,690 |
Other Revenue | 5.02 | 5.02 | 2.73 | 3.98 | 3.44 | 3.48 |
| 3,902 | 3,853 | 3,501 | 3,311 | 3,002 | 2,694 | |
Revenue Growth | 5.63% | 10.07% | 5.72% | 10.31% | 11.45% | 15.52% |
Cost of Revenue | 833.44 | 772.17 | 848.37 | 888.53 | 837.53 | 707.97 |
Gross Profit | 3,069 | 3,081 | 2,652 | 2,423 | 2,164 | 1,986 |
Selling, General & Admin | 2,004 | 2,042 | 1,762 | 1,675 | 1,608 | 1,483 |
Research & Development | 158.73 | 169.12 | 131.53 | 109.65 | 125.07 | 86.21 |
Other Operating Expenses | 44.92 | 41.6 | 29.69 | 44.84 | 40.54 | 37.4 |
Operating Expenses | 2,212 | 2,257 | 1,929 | 1,834 | 1,775 | 1,609 |
Operating Income | 857.1 | 824.36 | 723.74 | 588.93 | 389.07 | 376.45 |
Interest Expense | -4.17 | -4.17 | -0.26 | -0.2 | -1.14 | -1.9 |
Interest & Investment Income | 57.4 | 59.72 | 59.04 | 55.87 | 86.61 | 43.03 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0 | -0.01 | 0 | -0 |
Other Non Operating Income (Expenses) | -6.07 | -2 | -0.18 | -1.69 | -1.75 | -1.7 |
EBT Excluding Unusual Items | 904.24 | 877.91 | 782.35 | 642.9 | 472.79 | 415.88 |
Gain (Loss) on Sale of Investments | -2.88 | -7.32 | -0.01 | 0.12 | 5.93 | 0.05 |
Gain (Loss) on Sale of Assets | -3.63 | 1.09 | -3.9 | -0.63 | -0.1 | -20.32 |
Asset Writedown | -0.3 | - | - | -1.83 | - | - |
Other Unusual Items | 7.8 | 7.8 | 49.13 | 12.49 | 38.42 | 17.74 |
Pretax Income | 905.23 | 879.47 | 827.57 | 653.04 | 517.03 | 413.35 |
Income Tax Expense | 120.8 | 117.02 | 104.99 | 84.93 | 51.73 | 50.85 |
Earnings From Continuing Operations | 784.43 | 762.45 | 722.58 | 568.12 | 465.3 | 362.5 |
Minority Interest in Earnings | -4.23 | -2.94 | -0.03 | -0.01 | -0 | -0.96 |
Net Income | 780.21 | 759.5 | 722.55 | 568.11 | 465.3 | 361.54 |
Net Income to Common | 780.21 | 759.5 | 722.55 | 568.11 | 465.3 | 361.54 |
Net Income Growth | -0.47% | 5.11% | 27.18% | 22.09% | 28.70% | 11.08% |
Shares Outstanding (Basic) | 566 | 567 | 561 | 561 | 557 | 556 |
Shares Outstanding (Diluted) | 567 | 568 | 564 | 566 | 568 | 567 |
Shares Change | 0.47% | 0.64% | -0.42% | -0.30% | 0.26% | -0.24% |
EPS (Basic) | 1.38 | 1.34 | 1.29 | 1.01 | 0.84 | 0.65 |
EPS (Diluted) | 1.37 | 1.34 | 1.28 | 1.00 | 0.82 | 0.64 |
EPS Growth | -0.94% | 4.45% | 27.72% | 22.47% | 28.37% | 11.34% |
Free Cash Flow | 872.95 | 497.05 | 760.75 | 792.23 | 807.92 | 768.78 |
Free Cash Flow Per Share | 1.54 | 0.88 | 1.35 | 1.40 | 1.42 | 1.36 |
Dividend Per Share | 1.100 | 1.100 | 0.900 | 0.800 | 0.600 | 0.500 |
Dividend Growth | 22.22% | 22.22% | 12.50% | 33.33% | 20.00% | 25.00% |
Gross Margin | 78.64% | 79.96% | 75.77% | 73.17% | 72.10% | 73.72% |
Operating Margin | 21.96% | 21.39% | 20.67% | 17.78% | 12.96% | 13.98% |
Profit Margin | 19.99% | 19.71% | 20.64% | 17.16% | 15.50% | 13.42% |
Free Cash Flow Margin | 22.37% | 12.90% | 21.73% | 23.92% | 26.91% | 28.54% |
EBITDA | 953.11 | 919.58 | 795.48 | 664.74 | 463.4 | 447.63 |
EBITDA Margin | 24.43% | 23.86% | 22.72% | 20.07% | 15.44% | 16.62% |
D&A For EBITDA | 96.01 | 95.22 | 71.74 | 75.81 | 74.33 | 71.18 |
EBIT | 857.1 | 824.36 | 723.74 | 588.93 | 389.07 | 376.45 |
EBIT Margin | 21.96% | 21.39% | 20.67% | 17.78% | 12.96% | 13.98% |
Effective Tax Rate | 13.34% | 13.31% | 12.69% | 13.00% | 10.01% | 12.30% |
Revenue as Reported | 3,853 | 3,853 | 3,501 | 3,311 | 3,002 | 2,694 |
Advertising Expenses | - | 218.33 | 290.05 | 265.07 | 295.91 | - |